Back to results
RecruitingPhase 2

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

NCT06062498

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Northwestern University

Chicago, Illinois, United States

Contact

Study Coordinator

3126951301cancer@northwestern.edu
View on ClinicalTrials.gov
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer — TrialFind